Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

EGRIFTA

TESAMORELIN ACETATE

Standard Dose
EQ 1MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview EGRIFTA is listed in Drugs@FDA under application 022505 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TESAMORELIN ACETATE Form and strength POWDER;SUBCUTANEOUS - EQ 1MG BASE/VIAL Sponsor THERATECHNOLOGIES Submission history Latest submission status date: 2025-03-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview EGRIFTA is listed in Drugs@FDA under application 022505 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TESAMORELIN ACETATE Form and strength POWDER;SUBCUTANEOUS - EQ 1MG BASE/VIAL Sponsor THERATECHNOLOGIES Submission history Latest submission status date: 2025-03-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.